181 related articles for article (PubMed ID: 22845044)
1. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.
Kapil RP; Cipriano A; Michels GH; Perrino P; O'Keefe SA; Shet MS; Colucci SV; Noveck RJ; Harris SC
Clin Drug Investig; 2012 Sep; 32(9):583-92. PubMed ID: 22845044
[TBL] [Abstract][Full Text] [Related]
2. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
Wang Y; Cipriano A; Munera C; Harris SC
J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
[TBL] [Abstract][Full Text] [Related]
5. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
8. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
[TBL] [Abstract][Full Text] [Related]
9. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Shaik MN; LaBadie RR; Rudin D; Levin WJ
Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
[TBL] [Abstract][Full Text] [Related]
13. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
14. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
[TBL] [Abstract][Full Text] [Related]
15. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole greatly increases the exposure to oral buprenorphine.
Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
[TBL] [Abstract][Full Text] [Related]
17. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Steiner D; Munera C; Hale M; Ripa S; Landau C
J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
[TBL] [Abstract][Full Text] [Related]
20. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala YK; Tong W; Mount J; Rahavendran SV; Garrett M; Hee B; Selaru P; Sarapa N; Klamerus KJ
Invest New Drugs; 2012 Feb; 30(1):273-81. PubMed ID: 20740300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]